Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Journal of Immunology (Baltimore, Md. : 1950)|April 3, 2021
Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor HCristina Puy, Jiaqing Pang, Stéphanie E Reitsma, et al.Frontiers in Medicine|January 13, 2018
Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow ConditionsKathleen S Garland, Stéphanie E Reitsma, Toshiaki Shirai, et al.American Journal of Physiology. Cell Physiology|August 8, 2022
Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiologyTony J Zheng, Iván Parra-Izquierdo, Stéphanie E Reitsma, et al.Blood Advances|September 4, 2024
Plasmin generation analysis in patients with bleeding disorder of unknown causeDino Mehic, Stéphanie E Reitsma, Claire de Moreuil, et al.American Journal of Obstetrics and Gynecology|May 6, 2024
Agnostic identification of plasma biomarkers for postpartum hemorrhage riskStéphanie E Reitsma, Julia R Barsoum, Kirk C Hansen, et al.American Journal of Physiology. Cell Physiology|January 20, 2021
Role of platelets in regulating activated coagulation factor XI activityStéphanie E Reitsma, Jiaqing Pang, Vikram Raghunathan, et al.Frontiers in Immunology|September 16, 2021
The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell InteractionsIván Parra-Izquierdo, Hari Hara Sudhan Lakshmanan, Alexander R Melrose, et al.Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiencyStéphanie E Reitsma, Lori A Holle, Emma G Bouck, et al.Journal of Thrombosis and Haemostasis : JTH|August 30, 2024
Fibrinolysis is impaired in patients with primary immune thrombocytopeniaTheresa Schramm, Jasmin Rast, Dino Mehic, et al.Platelets|June 7, 2021
Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet functionIván Parra-Izquierdo, Alexander R Melrose, Jiaqing Pang, et al.Pageof 2